Siemens Healthineers ( (SEMHF) ) has released its Q4 earnings. Here is a breakdown of the information Siemens Healthineers presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Siemens Healthineers AG is a global leader in medical technology, specializing in diagnostic and therapeutic imaging, laboratory diagnostics, and advanced therapies. The company operates in the healthcare sector and is known for its innovative solutions and strong market presence.
In the fiscal year 2024, Siemens Healthineers reported solid financial performance, achieving revenue growth and earnings targets despite challenging market conditions, particularly in China. The company posted significant gains in the fourth quarter, contributing to an overall successful year.
Key financial highlights include a 4.7% increase in comparable revenue, a 15.7% adjusted EBIT margin, and a notable rise in net income by 28% compared to the previous year. The company’s Imaging, Varian, and Advanced Therapies segments drove substantial revenue growth. Free cash flow also saw a significant increase, reaching €2.1 billion, indicating robust cash generation.
Looking ahead to fiscal year 2025, Siemens Healthineers anticipates continued revenue growth of 5% to 6% and expects adjusted earnings per share to be between €2.35 and €2.50. The company remains optimistic about maintaining its momentum into the next financial year, despite uncertainties in the global economic environment.
